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Available online 11 May 2014Abstract Glioma stem-cell-like cells are considered to be responsible for treatment resistance and tumour recurrence following
chemo-radiation in glioblastoma patients, but specific targets by which to kill the cancer stem cell population remain elusive. A
characteristic feature of stem cells is their ability to undergo both symmetric and asymmetric cell divisions. In this study we have
analysed specific features of glioma stem cell mitosis. We found that glioma stem cells appear to be highly prone to undergo aberrant
cell division and polyploidization. Moreover, we discovered a pronounced change in the dynamic of mitotic centrosomematuration in
these cells. Accordingly, glioma stem cell survival appeared to be strongly dependent on Aurora A activity. Unlike differentiated cells,
glioma stem cells responded to moderate Aurora A inhibition with spindle defects, polyploidization and a dramatic increase in cellular
senescence, and were selectively sensitive to Aurora A and Plk1 inhibitor treatment. Our study proposes inhibition of centrosomal
kinases as a novel strategy to selectively target glioma stem cells.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
In the past decade, stem-cell-like cancer cells have been
identified in several tumours and implicated in treatment
resistance. Glioblastoma is one of the most extensively studied
cancer types in relation to treatment resistance and the cancer
stem cell (CSC)model. This is probably due to the poor outcome⁎ Corresponding authors.
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(http://creativecommons.org/licenses/by/3.0/).of patients treated for this disease (median overall survival of
14.6 months) (Stupp et al., 2009) and to the almost inevitable
recurrence following chemo-radiation, which renders glioblas-
tomas a valuable model for study of cancer cell resistance to
radiation and chemotherapy. Several clinical series have found
a correlation between glioma stem cell (GSC) features in
patient specimens (expression of putative GSC markers,
neurosphere formation ability in vitro) and tumour recurrence
and poorer prognosis (Strojnik et al., 2007; Zhang et al., 2008;
Zeppernick et al., 2008; Pallini et al., 2008). Furthermore, a
recent study using a genetically engineered mouse model of
glioma identified a relatively quiescent subpopulation of cellsaccess article under the CC BY license
136 M. Mannino et al.that was responsible for post-chemotherapy tumour growth,
through its capacity to produce transient subsets of highly
proliferating cells (Chen et al., 2012). These findings rein-
forced the rationale for the GSC theory and highlighted the
importance of processes regulating cellular growth, such as
DNA replication and mitosis, in the context of treatment
resistance.
Current standard therapy for glioblastoma consists of
debulking surgery followed by radiation with concomitant and
adjuvant administration of the alkylating agent temozolomide
(Stupp et al., 2009). Most studies investigating intrinsic GSC
resistance have focused on the role of DNA damage responses
and repair. However, experimental data from these studies are
conflicting and response mechanisms of GSCs to radiation and
chemotherapy remain controversial (Beier et al., 2011). Other
stem cell features, such as those involved in regulating cell
division, are only poorly understood in GSCs, but could provide
clinically relevant targets to improve treatment outcomes. A
paramount feature of stem cell mitosis is the ability to divide
both symmetrically and asymmetrically, giving rise to differen-
tiating daughter cells as well as maintaining a pool of
self-renewing stem cells (Lathia et al., 2011). Studies in fruit
fly neuronal stem cells have demonstrated a critical role for the
centrosome in establishing asymmetry during mitosis
(Yamashita et al., 2007). Centrosomes are the microtubule
organising centres in animal cells that form the poles of the
mitotic spindle. They are regulated by several mitotic kinases
including Aurora kinase A (AurA), Polo-like kinase 1 (Plk1) and
Cyclin dependent kinase 1 (Cdk1) (Nigg and Stearns, 2011).
Inhibitors of these kinases have long been implicated as
potential cancer therapies (Harrison et al., 2009). A recent
study has highlighted Plk1 inhibition as a strategy to selectively
kill GSC enriched populations (Lee et al., 2012). Moreover, AurA
is overexpressed in glioblastomas (Loh et al., 2010; Lehman et
al., 2012); its expression levels have been correlated with
patient outcome (Barton et al., 2010); and data from other
tumour sites suggest a role for AurA in CSC behaviour
(Cammareri et al., 2010; Chefetz et al., 2011). However, a
link between centrosome biology, mitotic kinase inhibition and
GSC targeting has not been established.
In this study we analysed centrosome and mitotic spindle
morphology in glioblastoma stem cell enriched and differen-
tiated populations. We report a higher frequency of abnormal
spindles and a more pronounced maturation of centrosomes
preceding mitosis in GSC enriched populations. This prompted
us to investigate whether differences in mitotic spindle dy-
namics could provide a novel therapeutic strategy by which
GSC populations could be specifically targeted. We show that
AurA and Plk1, both involved in centrosome maturation and
bipolar spindle assembly can be targeted to kill GSCs more
effectively, and propose that this strategy might improve
outcomes for patients with glioblastoma.
Results
Neurosphere cultures of primary glioblastoma cells
generate invasive intracranial xenografts in
immunodeficient mice
Consistent with previously published data (Fael Al-Mayhani et
al., 2009), primary glioblastoma cells cultured as non-adherentneurospheres in serum-free medium expressed high levels
of stem cell markers including CD133, nestin and Sox2 (Fig. 1A,
supplementary Fig. S1A,B), low levels of astrocytic differen-
tiation markers including GFAP (supplementary Fig. S1B) and
generated invasive intracranial xenografts in CD1 nude mice.
Intracranial injection of 105 E2 cells cultured as neuro-
spheres (‘E2 GSC’) generates tumours in 100% of mice and
these tumours were highly invasive. In addition to a mass at
the injection site (Fig. 1B), tumour cells identified by human
specific HLA-1ABC and Ki67 stainingwere detected throughout
both hemispheres (Supplementary Fig. S1C). Quantitative
analysis of Ki67 positive cells in whole brain slices harvested
at various timepoints demonstrated increasing tumour cell
burden up to 20 weeks after injection (Fig. 1B, supplementary
Fig. S1C). In contrast, injection of 105 E2 cells cultured as
monolayers in serum-containing medium (‘E2 diff’) failed to
generate tumourmasses and tumour cells did not infiltrate the
brain. Very low numbers of HLA-1ABC or Ki67 positive cells
were detected (Fig. 1B). Injection of 105 G7 cells cultured as
neurospheres (‘G7 GSC’) generated tumours in 100% of mice;
all tumours were highly invasive at the tumour margins
(Fig. 1B). Injection of 105 G7 cells cultured as monolayers in
serum-containing medium (‘G7 diff’) also generated tumours
but these had well defined edges and did not exhibit the
invasive pattern observed in G7 GSC derived tumours (Fig. 1B).Glioblastoma stem cells are prone to mitotic
failure and show a distinct pattern of
centrosome maturation
Cell division of GSCs remains scarcely characterised, despite
its role in maintaining stemness and generating cellular
diversity (Lathia et al., 2011). To understand whether mitosis
in these cells presents specific features that can be targeted
therapeutically, we analysed their mitotic spindles by immuno-
fluorescence. GSC enriched populations had a significantly
higher frequency of abnormal mitotic spindles (monopolar or
multipolar) compared tomore differentiated populations: 14%
vs. 4%, respectively (Fig. 1C). While scoring mitosis in the GSC
enriched populations we frequently observed cells with two
or more nuclei (Fig. 1C). To clarify whether these were cell
aggregates or truly polyploid cells, we stained both cell pop-
ulations with phalloidin to visualise the cell cortex. This
allowed us to differentiate between single cells with two or
more nuclei and closely attached cells with two single nuclei.
Consistentwith themitotic spindle data, this analysis revealed
that GSC enriched populations had a much higher percentage
of polyploid cells compared to more differentiated popula-
tions: 25% vs. 6%, respectively (Fig. 1D). In order to test
whether the increase in abnormal spindles was due to growth
in suspension, we analysed spindle phenotypes in differenti-
ated cells cultured as non-adherent aggregates and found
that all imaged cells had bipolar spindles (data not shown),
suggesting that the neurosphere growth is not a confounding
factor for the observed mitotic phenotypes. To our knowl-
edge, this is the first study reporting a higher frequency of
abnormal mitotic spindles and polyploidy in GSC enriched
populations in vitro.
While analysing spindle morphology we noted a distinct
pattern in the distribution of γ-tubulin at the centrosomes in
the GSC populations that was characterised by a marked
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Figure 1 Primary glioblastoma cells cultured as neurospheres in serum-free conditions express high levels of stem cell markers, form
invasive intracranial xenografts in immunodeficient mice and have a higher frequency of abnormal mitotic spindles and a distinct
pattern of centrosome maturation. (A) Immunoblot analysis of lysates of E2 and G7 primary glioblastoma cell cultures was performed,
probing for the stem cell markers Sox2 and nestin, with tubulin and actin as loading controls (GSCs—glioma stem cells cultured as
neurospheres in serum-free medium, diff.—differentiated, adherent cells cultured in serum-containing medium) (B) Immunohisto-
chemistry was performed on sections of brains of CD1 nude mice that had been injected with 105 E2 or G7 glioblastoma cells that had
been cultured to enrich for GSC or to promote differentiation. Sections were stained for Ki67 (G7 images on left) to interrogate local
brain invasion and for HLA-1ABC to identify tumour cells of human origin (E2 images below histogram). To measure tumour cell burden
in highly infiltrative E2 derived xenografts, quantitative analysis of Ki67 positive cells in whole brain sections was performed using
ZenBlue software. Number of Ki67 positive cells per section was plotted against time after injection of E2 GSC and differentiated cells
(Scale bar at 50 μm). (C) Cells were stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualise the mitotic spindle
morphology: on the left, a diagram shows the percentages of normal and abnormal spindles in glioma stem cells and differentiated
cells. On the right are representative images of mitotic phenotypes (Scale bar 2 μm). PN: polynucleated cells. An average of 26 mitotic
cells/condition/experiment were identified randomly and scored (*p = 0.0232, two tailed t-test). (D) Cells were stained with
phalloidin (red) and DAPI (blue) to visualise the cell cortex and nucleus: on the left are representative images of GSC and diff. cells
(scale bar 10 μm); on the right, a diagram shows the percentages of polynucleated cells in the two populations. An average of 251
cells/condition/experiment were identified randomly and scored (***p = 0.000275, two tailed t-test).
137Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitorsincrease in γ-tubulin at the mitotic centrosomes compared to
differentiated cells. Given the role of centrosomes in bipolar
spindle assembly, we further analysed the distribution of
γ-tubulin in the two glioblastoma cell populations. For this
purpose we measured the size of the γ-tubulin area in bothinterphase and mitotic cells (Fig. 2A). The specificity of
the centrosomal γ-tubulin staining was confirmed by co-
localization with centrin (supplementary Fig. S2A). This quan-
titative analysis revealed a more pronounced centrosomal
accumulation of γ-tubulin at mitosis in GSCs, compared to
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Figure 2 Glioblastoma stem cells have more abnormal spindles following treatment with Aurora A inhibitors. (A) Cells were stained
for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualise the accumulation of γ tubulin during centrosome maturation: at the
top are representative images of GSC and diff. cells (scale bar 5 μm), with inserts showing γ tubulin staining in interphase (I) and
mitotic (M) cells (scale bar 500 nm); at the bottom, a diagram shows the ratio between centrosomal γ-tubulin in mitotic and
interphase cells, as a measure of centrosome maturation, in GSC and diff. populations. An average of 144 cells/condition/experiment
were identified randomly and scored. All results are representative of three independent experiments. Error bars indicate means ±
SD. (B) Cells were stained for P-AurA (red) and mitotic cells were analysed: on the left, a box plot shows the quantification of P-AurA
in mitotic centrosomes in diff. and GSC cells; on the right are representative images of mitotic cells in the two populations (scale bar
2 μm). An average of 22 mitotic cells/condition/experiment were identified randomly and scored. (C–D) Cells were treated with
MLN8237 (0, 25, 50 and 100 nM) and after 24 h they were fixed and stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to
visualise the mitotic spindle morphology. (B) On the left, two diagrams show the distribution of different spindle phenotypes in GSC
and diff. cells; on the right a diagram shows the percentages of abnormal mitotic spindles in the two populations. (C) Representative
images of GSC and diff. cells ± MLN8237 (scale bar 2 μm). An average of 26 mitotic cells/condition/experiment were identified
randomly and scored. All results are representative of three independent experiments. Error bars indicate means ± SD.
138 M. Mannino et al.differentiated cells (Fig. 2A). Thus, centrosome matura-
tion, measured as the ratio between centrosomal γ-tubulin
in mitotic and interphase cells, was increased more than
twofold in GSCs. This finding, together with the differencein mitotic phenotypes, highlights the importance of
investigating in detail GSC division and the processes
leading to it, in order to find effective and specific ways
of targeting this population.
139Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitorsGlioblastoma stem cell enriched populations have
more abnormal spindles following treatment with
Aurora A inhibitors
Since GSCs display a more pronounced accumulation of γ-
tubulin at the centrosome during mitotic entry, we reasoned
that this could be an interesting point of attack for a targeted
therapeutic approach. For this purpose we focused on AurA,
which is a major regulator of mitotic centrosome maturation.
The differences in centrosome dynamics could not be attri-
buted to different levels of activity of AurA in the two cell
populations (supplementary Fig. S2B–C and Fig. 2B). To
analyse the requirement for AurA activity in the two popula-
tions, we treated stem and differentiated glioma cells with
the AurA inhibitor MLN8237, using low dose levels that only
had subtle effects on overall AurA kinase activity (supplemen-
tary Fig. S2C). Given that MLN8237 has a selectivity of more
than 200-fold for AurA over Aurora kinase B (Manfredi et al.,
2011), we can assume that any observed effects are AurA
specific. Interestingly, treatment with the inhibitor induced
more abnormal spindles in GSC enriched populations at all
dose levels compared tomore differentiated cells: 56% vs. 14%
at 25 nM, 75% vs. 29% at 50 nM and 79% vs. 47% at 100 nM,
respectively (Fig. 2C). The two populations of cells also
exhibited a different response to AurA inhibition in terms of
the type of spindle defect. GSC enriched populations showed a
dramatic increase only in monopolar spindles, while their
more differentiated counterparts showed amoderate increase
in both monopolar and multipolar spindles (Fig. 2C). Fig. 2D
shows representative images of treated cells. These data0
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AurA activity.
Aurora A inhibition induces an increase in polyploidy
To further understand the consequences of AurA inhibitor
treatment on GSCs we analysed parameters of cell cycle
distribution in the two cell populations. Several studies have
reported a G2/M arrest following inhibition of AurA, either
by small molecule inhibitors or by RNAi (Gorgun et al., 2010).
In our study the baseline cell cycle profiles of the two
populations differed significantly: GSC enriched populations
had a higher percentage of cells with 4 N and N4 N DNA
content (Fig. 3A). Cells with a 4 N FACS profile can be in G2,
M or a quatroploid G1 phase. To distinguish between these
cell cycle states, we scored the percentage of cells in G2 and
M by immunofluorescence using CENP-F, α-tubulin and DAPI
staining (for a representative example, see Fig. 3B). The G2/
M fraction was similar in the two populations, confirming
that the difference in cells with 4 N DNA content was due to
polyploidy. Cell cycle profiles of the two populations 24 h
after treatment with MLN8237 showed an increase in the 4 N
and N4 N DNA content fraction in both populations. Immuno-
fluorescence analysis showed only subtle increases in the
percentage of G2 and M phase cells after treatment, sug-
gesting that AurA inhibition does not induce a prolonged G2/
M arrest in these cells, despite a significant increase of
mitotic aberrations following MLN8237 treatment (Fig. 2).
To confirm and characterise the moderate increase in the
≥4 N fraction, we stained with phalloidin cells after AurAG1 S G2/M 4N
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Figure 4 Glioblastoma stem cells are killedmore efficiently by MLN8237. (A) Cells were treated with MLN8237 (0, 25, 50 and 100 nM)
and after 24 h they were fixed, stained with phalloidin (red) and DAPI (blue), to visualise the cell cortex and nucleus: on the left are
representative images of GSC and diff. cells (scale bar 10 μm); on the right, a diagram shows the percentages of polynucleated cells in
the two populations ± MLN8237. An average of 221 cells/condition/experiment were identified randomly and scored. (B) Cells were
incubated separately with CellTracker Green and Blue, re-suspended in fresh medium, incubated for 24 h ± 50 nM MLN8237 and then
fixed and stained with phalloidin: representative images of sphere cells ± MLN8237 (scale bar 10 μm). (C) Clonogenic assays showing
survival of sphere and adherent cells ± MLN8237. (D) Cells were treated with MLN8237 (0 and 50 nM) and after 2 or 7 days they were
fixed and stained for β-galactosidase: on the left, a diagram shows the percentages of senescent cells in the two populations ±
MLN8237; on the right are representative images of sphere and adherent cells ± MLN8237. (scale bar 10 μm). An average of 233 cells/
condition/experiment were identified randomly and scored. All results are representative of three independent experiments. Error
bars indicate means ± SD.
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141Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitorsinhibition. This analysis detected an increasing number of
giant polynucleated cells that was more pronounced in the
GSC population: 37%, 47% and 54% of these cells were poly-
ploid after 25, 50 and 100 nM treatments, compared with
12%, 12% and 20% in the more differentiated populations
(Fig. 4A). That these percentages were higher than indicated
by the FACS data is probably explained by the large size of
some polyploid cells causing them to evade FACS analysis.
Polyploidy can be caused by several mechanisms: abnormal
mitosis, endoreduplication, cell fusion and entosis (Krajcovic
and Overholtzer, 2012). Given that cell appearance does not
distinguish between the products of cell fusion and mitotic
failure, and that entosis has been observed mainly under
non-adherent growth conditions (Overholtzer et al., 2007), we
tested the extent to which these different processes were
responsible for baseline and post-treatment levels of poly-
ploidy amongst GSCs. Cells were marked separately with cell
tracking dyes, mixed then incubated for 24 h with or without
MLN8237 (Fig. 4B). In both treated and untreated samples the
vast majority of polyploid cells originated from the same
mother cell, suggesting that in GSCs polyploidy is not a result
of cell fusion or entosis, but rather a consequence of mitotic
defects.Increase in polyploidy correlates with increased
sensitivity to Aurora A inhibition and induction
of senescence
Our analysis suggests that GSCs are prone to undergoing
mitotic failure and are highly susceptible to subtle changes
in AurA activity levels. The observed increase in monopolar
spindles does not cause a prolonged mitotic arrest suggest-
ing that these cells are prone to mitotic slippage. This is
also reflected in the rapid polyploidization observed after
MLN8237 treatment. Taken together these observations
indicate that chemical inhibitors of mitosis might be useful
therapeutic agents that specifically target the GSC popula-
tion. We tested this hypothesis by measuring the sensitivity
of glioblastoma stem cell enriched and more differentiated
populations to MLN8237 and found that two independent
GSC lines were indeed killed more efficiently by the AurA
inhibitor (Fig. 4C). We further tested our hypothesis by
analysing the effect on clonogenicity of inhibiting another
centrosome kinase, Plk1, with BI2536: again, two indepen-
dent GSC lines had a lower survival than their differentiated
counterparts (supplementary Fig. 3).
In order to understand the cause of death in glioblastoma
stem cell enriched and more differentiated populations
following AurA inhibition, we measured levels of apoptosis
and senescence. While MLN8237 did not increase apoptosis
as judged by cleaved Caspase 3 levels in either popula-
tion (supplementary Fig. 4A), a significant increase in the
number of senescent cells was observed. Seven days after
AurA inhibition, 55% of GSCs expressed a marker of senes-
cence, compared with only 19% of differentiated cells
(Fig. 4D). The negligible level of apoptosis is consistent with
some published studies (Huck et al., 2010; Liu et al., 2013)
but not with others (Gorgun et al., 2010). Recent literature is
also conflicting with regard to the correlation between cell
fate following AurA inhibition and p53 status (Liu et al., 2013;
Nair et al., 2012; Liu et al., 2013). To test whether thedifferent response to MLN8237 was due to p53 status, we
analysed levels of p53 expression in glioblastoma stem cell
enriched and more differentiated populations in three
primary cell lines: there was no common pattern of p53
levels in the various cell lines when comparing the two
subpopulations (supplementary Fig. 4B–D). This suggests
that the increased sensitivity of GSCs to AurA inhibition is not
dependent on p53 status.
Several studies in a variety of cancer models have shown
that cellular senescence is induced in vivo by chemotherapy
and radiotherapy (Roninson, 2003). Although a large body of
evidence links senescence to tumour suppression, recent
data suggests that, in a minority of cancer cells, senescence
associated polyploidy can be reversible and might consti-
tute a survival mechanism. A clinicopathological analysis of
specimens from patients with non-small cell lung cancer
undergoing surgery after neo-adjuvant chemotherapy showed
that β-galactosidase staining was correlated with de-
creased overall survival (Wang et al., 2013). Moreover,
one of the features of senescent cells is the acquisition of a
secretory phenotype, which creates a niche that can affect
adjacent cells (Rodier and Campisi, 2011). Amongst the
released factors is IL-6 (Coppe et al., 2008), which has been
reported to promote GSC survival and tumour growth (Wang
et al., 2009). These findings suggest a possible link between
chemotherapy-induced senescence, GSCs and treatment
resistance. Our survival data clearly indicate that senes-
cence following MLN8237-induced mitotic failure causes a
reduction of neurosphere formation in GSCs and generally
decreases the clonogenic potential of glioma cells. Hence
we propose that induction of senescence by polyploidy
could be a promising anticancer strategy that targets GSCs,
rather than a survival mechanism. Given the limitations of a
single cell survival assay in this context, our findings highlight
the need for in vivo studies and pathological analysis to clarify
the role of senescence associated polyploidy in GSC biology
and treatment outcomes.
Another significant outcome of our study is the differ-
ence in centrosome maturation and mitotic spindle pheno-
types between GSC enriched and differentiated populations.
To our knowledge there are no previous reports on this
aspect of GSC biology. The high susceptibility of GSCs to
subtle changes in levels of kinases involved in the centro-
some cycle is particularly interesting if we consider the
literature on the role of symmetric and asymmetric divisions
in cancer. Defects in regulation of switch between asym-
metric and symmetric divisions have been speculated to be
involved in carcinogenesis (Morrison and Kimble, 2006), and
therefore might be strongly linked to generation of GSCs.
GSCs in vitro divide mainly by symmetric division, but are
able to increase the asymmetric mode following growth
factor withdrawal, i.e. a differentiation stimulus (Lathia
et al., 2011). Normal adult stem cells seem to switch
from asymmetrical to symmetrical division following injury
(Morrison and Kimble, 2006). The study mentioned previous-
ly (Chen et al., 2012), which used a genetically engineered
mouse model of glioma, reported data on transient subsets
of highly proliferating tumour cells post-chemotherapy. In
this study the growth patterns were consistent with an initial
prevalence of symmetric divisions followed by a switch to
asymmetrical mode. Based on this data and on our findings,
we speculate that GSC mitosis confers more plasticity and
142 M. Mannino et al.increased regenerative ability to these cells, but also
renders them more susceptible to mitotic failure.
Mechanisms regulating mitosis, as well as senescence, in
GSCs, are still poorly understood and need to be investigated
further, especially with pathology studies that would be able
to confirm whether our in vitro findings apply to GSCs in
their natural microenvironment.
Materials and methods
Cell lines and cell culture
E2 and G7 primary glioblastoma cell lines were derived from
freshly resected GBM specimens as previously described (Fael
Al-Mayhani et al., 2009) and generously provided by Colin
Watts (Cambridge). Tissue collection protocols were compli-
ant with the UK Human Tissue Act 2004 (HTA Licence ref
12315) and approved by the local regional Ethics Committee
(LREC ref 04/Q0108/60). Informed consent was obtained
from each patient before surgery. Briefly, anonymised pa-
tient resection specimens were homogenised and seeded in
serum free (SF) media to form spheroid aggregates which
were then collected and plated onto extracellular matrix
coated flasks. (ECM 1:10 dilution, Sigma). Cells were allowed
to form a primary monolayer then passaged in SF medium.
Each cell line was subsequently cultured as paired cancer
stem cell enriched (GSC) and differentiated (diff) cell lines
by passaging in either SF media or differentiating media
(DM). GSC enriched populations were cultured as neuro-
spheres in Neurobasal-A medium (Invitrogen) supplemented
with B-27 (Invitrogen), epidermal growth factor (20 ng/ml,
Invitrogen PHG0313), fibroblast growth factor (20 ng/ml,
Invitrogen PHG0263), glutamine and penicillin/streptomycin
(referred to as ‘sphere cells’ or ‘GSC’ in figures). Differen-
tiated populations were derived from these cells by culturing
them as adherent cells in MEM supplemented with HyClone
(Thermo Scientific HyClone, 12822966), NEAA, glutamine
and penicillin/streptomycin (referred to as ‘adherent’ or
‘diff’ cells in figures).
Reagents
In all experiments with AurA inhibition we incubated cells
with MLN8237 (Millenium) for 24 h. For clonogenic survival
assays we added the reagents to the plates and left them for
the whole duration of the experiment.
Immunostaining
For centrosome maturation, mitotic spindle and cell cycle
analysis, cells were collected from flasks, spun down, re-
suspended, pipetted on Concanavalin A (Sigma) coated cov-
erslips and fixed with 70% methanol for 5 min. For P-AurA
analysis, cells were cytospun on Concanavalin A coated
coverslips and fixed with 4% paraformaldehyde and 70%
methanol, sequentially for 5 min each. Cells were perme-
abilized in PBS 0.3% Triton for 5 min, blocked in 3% BSA for
30 min and probed with primary antibodies for 60 min. Slides
were rinsed and probed with Alexa Fluor secondary antibod-
ies (Invitrogen) for 60 min. Coverslips were mounted usingProLong Gold mounting solution containing DAPI (Molecular
Probes). The following primary antibodies were used: HLA
Class 1ABC (EMR8-5, Abcam ab70328), Ki67, CD133, nestin,
Sox2, GFAP, α tubulin (Abcam ab7291, ab18251), γ tubulin
(Abcam ab11316), centrin-2 (gift from Elmar Schiebel),
CENP-F (Abcam ab5), and P-AurA (Cell Signalling 3079).
Images were acquired on a microscope (DeltaVision)
equipped with a UPLS Apochromat NA 1.40, 60× or 100× oil
immersion objective (Olympus), standard filter sets (excita-
tion 360/40, 490/20, and 555/28; emission 457/50, 528/38,
and 617/40), and a camera (CoolSNAP HQ2; Photometrics). Z
series of 0.3 μm stacks were acquired using softWoRx soft-
ware (version 4.0.0; Applied Precision) and deconvolution was
performed using SVI Huygens Professional Deconvolution
Software (Version 3.5). For quantitative data on γ tubulin
and P-AurA centrosomal localization, DeltaVision files were
imported into Imaris software (version 6.3.0; Bitplane) for 3D
rendering measurements using the surface rendering algo-
rithm for γ tubulin and P-AurA signals. Measurements were
then exported to Excel (Microsoft) and plotted. The data was
further analysed using Mann–Whitney U test.
For ploidy analysis, cells were collected from flasks, spun
down, re-suspended, pipetted on Concanavalin A coated cov-
erslips and fixed with 4% paraformaldehyde for 10 min. Cells
were permeabilized, blocked and probed with phalloidin
(Invitrogen) for 30 min. Coverslips were mounted as above.
FACS analysis
It was performed as previously described (Hegarat et al.,
2011).
Cell tracking
Cells were incubated separately with 1 μM CellTracker Green
CMFDA (5-Chloromethylfluorescein Diacetate) and 1 μM
CellTracker Blue CMAC (7-Amino-4-Chloromethylcoumarin)
(both from Molecular Probes) for 45 min, spun down, re-
suspended in fresh medium and incubated for 24 h ±50 nM
MLN8237. Cells were then fixed and stained with phalloidin
as in the ploidy analysis. Coverslips were mounted using
Fluoromount (Sigma).
Clonogenic survival assay
Clonogenics were performed plating the cell suspension in 96
well plates, at an ideal concentration of 1 cell/well (200 μl).
Each subpopulation of cells was plated in the appropriate
medium. EGF and FGF are added to the GSC plates on days 5,
10 and 15. Neurospheres and adherent colonies were counted
on day 21 using the Gel Count (Oxford Optronix) and meth-
ylene blue staining, respectively.
β-galactosidase staining
Cells were treated with MLN8237 and after 2 and 7 days they
were fixed and stained for β-galactosidase according to the
manufacture's protocol (Abcam). Images were acquired on a
microscope Axio Lb A1 (Zeiss) equipped with an AxioCam ERc
5 s and a 40× objective.
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